Venrock stocks up on $450M Fund 8 as it prepares a new string of biotech deals
The venture partners at Venrock have an appetite for high-risk biotechs looking to break new ground. Now they have a new $450 million fund to satisfy themselves with a steady diet of new deals ahead.
Bryan Roberts, a partner specializing in healthcare who was in on Receptos early on — well before Celgene acquired it for $7.2 billion — used a blog post on the VC’s site to announce the new fund, Venrock’s 8th. He wrote:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.